• Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update

  • Oct 1 2024
  • Duración: 32 m
  • Podcast

Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Approval of BMS’s first-in-class schizophrenia drug is good news for patients and the company’s thinning pipeline alike, but maximizing Cobenfy’s commercial potential depends on readouts in additional indications. On the latest BioCentury This Week podcast, BioCentury’s editors assess the significance of the new therapy and what the pharma needs to do to make its launch a success.
    They also discuss the impact of the withdrawal of Pfizer's sickle cell therapy; the work left unfinished on biotech-related legislation in Congress; BioAge's NASDAQ IPO; and the importance of FDA’s Oncologic Drugs Advisory Committee meeting on the use of PD-1 inhibitors in patients with certain tumors expressing low levels of PD-L1. This episode of BioCentury This Week was sponsored by Parexel Biotech.

    View full story: https://www.biocentury.com/article/653732

    00:01 - Sponsor Message: Parexel BioTech
    01:41 - BMS Schizophrenia Drug
    12:28 - Pfizer Withdrawal's Oxbryta
    18:26 - ODAC and PDL1
    23:56 - D.C. Update
    26:51 - BioAge IPO

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

    Reach us by sending a text
    Más Menos
activate_Holiday_promo_in_buybox_DT_T2
Más Menos

Lo que los oyentes dicen sobre Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles